Skip to content

Ketamine for depression: all studies

Page 53 of 178: studies 521 to 530 of 1,775, newest first. Back to the ketamine for depression overview

Research

Racial-Ethnic Disparities in Ketamine and Esketamine Therapy for Major Depressive Disorder.

Psychiatric Services June 25, 2025 Michael Liu, Rachel Branning, Austin Lee et al. 2 citations

This study sought to investigate racial-ethnic disparities in the utilization of intravenous ketamine and intranasal esketamine therapy for major depressive disorder. The TriNetX platform was used to identify 861,179 patients diagnosed as having moderate-to-severe recurrent major depressive disorder between January 2019 and October 2024. Patients were divided into non-Hispanic White,...

DOI: 10.1176/appi.ps.20240559 (opens in new tab) Full text (opens in new tab) Esketamine Racial-ethnic disparities Unequal access Healthcare disparities +10

MeCP2 prevents against sustained ketamine-induced synaptic depression at inhibitory synapses.

iScience June 20, 2025 Michelle K Piazza, Abigael R Weit, Ege T Kavalali et al. 2 citations

Ketamine induces antidepressant action via upregulation of hippocampal brain-derived neurotrophic factor (BDNF) expression and TrkB receptor signaling. Rett syndrome (RTT), a neurodevelopmental disorder caused by mutations in Methyl-CpG-binding protein 2 (MECP2), is associated with decreased BDNF expression. Although treatment with ketamine or LM22A-4, a TrkB receptor agonist, improves...

DOI: 10.1016/j.isci.2025.112485 (opens in new tab) Full text (opens in new tab) Ketamine Biological sciences Molecular neuroscience Natural sciences +3

Comparing the effects of ECT and intravenous ketamine in psychiatric patients with major depressive episodes.

Journal of Affective Disorders June 18, 2025 Julia Myerson, Katrina A Rufino, Sanjay J. Mathew et al.

Electroconvulsive therapy (ECT) and intravenous (IV) ketamine are treatments used for severe depression and/or treatment-resistant depression (TRD). ECT is considered one of the most effective treatments for severe depression, although there is debate within the field regarding the effectiveness between ECT and IV ketamine in comparable TRD patient groups. This retrospective chart review of...

DOI: 10.1016/j.jad.2025.119727 (opens in new tab) Full text (opens in new tab) Depression Effectiveness Major depressive episodes Mental health treatment +10

The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression

The British Journal of Psychiatry June 18, 2025 Kyle T. Greenway, Nicolas Garel, Lê-Anh Dinh-Williams et al. 8 citations

Background Ketamine exerts potent but transient antidepressant effects in treatment-resistant depression (TRD). Combinations of ketamine and psychotherapy have attracted interest, but no trial has investigated a psychedelic model of ketamine–psychotherapy for TRD to our knowledge. Aims This secondary analysis of a randomised clinical trial (RCT) explores the therapeutic effects and experiential...

Sex and Age Differences in Ketamine Efficacy and Safety in Chronic Pain Alleviation.

Journal of Clinical Medicine June 16, 2025 Gisèle Pickering, Marion Voute, Marc Sorel et al. 2 citations

Background: Ketamine use for chronic pain and depression has increased worldwide, but sex differences in its efficacy and safety have been little studied; this study examines existing evidence to address this gap. Methods: A prospective, multicenter, one-year observational study in 585 chronic pain patients was performed; 256 patients had one administration of ketamine and 329 had two or more....

DOI: 10.3390/jcm14124269 (opens in new tab) Full text (opens in new tab) Refractory pain Sex Ketamine therapy Chronic pain management +2

Network localization of functional brain changes associated with ketamine's therapeutic effects in depression.

Biological Psychiatry June 13, 2025 Shaoqiang Han, Ya Tian, Huiting Yang et al. 1 citation

Although numerous studies have attempted to identify the functional pathways underlying the rapid antidepressant effects of ketamine, their findings remain inconsistent, limiting our understanding of the neural mechanisms involved. This study aims to delineate a specific brain circuit by integrating diverse functional findings related to ketamine's efficacy in depression. We conducted a...

DOI: 10.1016/j.biopsych.2025.06.006 (opens in new tab) Full text (opens in new tab) Ketamine: ketamine Therapeutic effects Unique power Depression: depression +8

The pattern of dissociative symptoms differs between post-traumatic stress disorder and first esketamine administration for treatment-resistant depression.

Journal of Affective Disorders June 12, 2025 David Williamson, Linda Williamson, Viola Vaccarino et al. 2 citations

Dissociative symptoms are commonly observed in a substantial minority of patients with Post-Traumatic Stress Disorder (PTSD) and during the first administration of esketamine for the treatment of Treatment-Resistant Depression (TRD). We examine differences in the number and pattern of dissociative symptoms (depersonalization, derealization, dissociative amnesia, identity fragmentation) reported...

DOI: 10.1016/j.jad.2025.119632 (opens in new tab) Full text (opens in new tab) Nmda receptor antagonists Posttraumatic Stress Treatment resistant depression +6

Unveiling the Anti-Inflammatory Effects of Antidepressants: A Systematic Review of Human Studies over the Last Decade.

Pharmaceuticals June 10, 2025 Layla Bleibel, Paulina Sokołowska, Gabriela Henrykowska et al. 18 citations

Background/Objectives: Depression ranks among the most prevalent mental health conditions globally, marked by a variety of symptoms that frequently cause significant emotional distress and impairment in individuals, alongside a high recurrence rate. The predominant approach to treating depression revolves around monoamine theory, utilizing SSRIs and SNRIs, with Esketamine emerging as a...

Prophylactic esketamine for postpartum depression after cesarean section: a systematic review and meta-analysis.

Journal of Affective Disorders June 10, 2025 Haibin Shi, Caihong Zheng, Bin Zhu 5 citations

According to recent research, esketamine may reduce the incidence of postpartum depression (PPD) risk following cesarean delivery. To further assess this potential benefit, a meta-analysis was conducted. Embase, Web of Science, the Cochrane Library, and PubMed were searched from inception through March 2025. Meta-analysis was performed using random-effects models to calculate risk ratios (RRs)...

DOI: 10.1016/j.jad.2025.119631 (opens in new tab) Full text (opens in new tab) Meta-analysis Postpartum depression ppd Postnatal depression Cesarean section c-section +4

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression.

Journal of comparative effectiveness research June 9, 2025 Kristin Clemens, Amanda Teeple, Benoit Rive et al.

Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS + OAD) versus quetiapine extended release plus an oral antidepressant (QTP XR + OAD) among adults with treatment-resistant depression (TRD). Materials & methods: An Excel-based model was developed to estimate the cost-per-remitter for ESK NS + OAD and QTP XR + OAD from the perspective of a US...